Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial

Arthritis Rheum. 2006 Feb;54(2):678-81. doi: 10.1002/art.21563.

Authors

Hildrun Haibel¹, Martin Rudwaleit, Henning C Brandt, Zarho Grozdanovic, Joachim Listing, Hartmut Kupper, Jürgen Braun, Joachim Sieper

Affiliation

¹ Benjamin Franklin Hospital, Berlin, Germany.

PMID: 16447247
DOI: 10.1002/art.21563

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab
Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Female
Humans
Injections, Subcutaneous
Magnetic Resonance Imaging
Male
Middle Aged
Pilot Projects
Sacroiliac Joint / drug effects
Sacroiliac Joint / pathology
Severity of Illness Index
Spine / drug effects
Spine / pathology*
Spine / physiopathology
Spondylitis, Ankylosing / drug therapy*
Spondylitis, Ankylosing / pathology
Spondylitis, Ankylosing / physiopathology
Treatment Outcome
Tumor Necrosis Factor-alpha / immunology*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Adalimumab